Skip to main content

Table 1 Baseline characteristics of patients in the ascend group and the stable group

From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Characteristics

Ascend group (n, %)

Stable group (n, %)

P

Gender

  

0.346

 Male

30 (49.2)

7 (36.8)

 

 Female

31 (50.8)

12 (63.2)

 

Age (median, range)

62 (40~84)

69 (40~84)

0.362

Body weight loss

  

1.000

 <5 %

58 (95.1)

19 (100.0)

 

 ≥5 %

3 (4.9)

0 (0.0)

 

Smoking status

  

0.401

 Never-smokers

41 (67.2)

15 (78.9)

 

 Smokers

20 (32.8)

4 (21.1)

 

ECOG PS

  

1.000

 0~1

58 (95.1)

18 (94.7)

 

 ≥2

3 (4.9)

1 (5.3)

 

Pathology

  

1.000

 Adenocarcinoma

58 (95.1)

18 (94.7)

 

 Non-adenocarcinoma

3 (4.9)

1 (5.3)

 

Clinical stage

  

1.000

 IIIB

1 (1.6)

0 (0.0)

 

 IV

60 (98.4)

19 (100.0)

 

Line of EGFR-TKI

  

0.371

 First-line

36 (59.0)

9 (47.4)

 

 ≥Second-line

25 (41.0)

10 (52.6)

 

EGFR-TKI

  

0.946

 Erlotinib

23 (37.7)

7 (36.8)

 

 Gefitinib

38 (62.3)

12 (63.2)

 

Basic level of plasma L858R mutation (median, range)

20.0 (0.97~109.43)

27.45 (3.56~112.9)

0.184

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor